8-K Announcements
6Material company update
May 6, 2026·SEC
Material company update
Apr 3, 2026·SEC
Material company update
Mar 16, 2026·SEC
KORU Medical Systems, Inc.(KRMD)Earnings, Financials & Key Ratios
KRMD•NASDAQ
$4.01
$187M mkt cap·Price updated May 6, 2026
AboutKORU Medical Systems, Inc. designs, manufactures, and markets portable medical devices primarily for the ambulatory infusion market in the United States and internationally. It offers mechanical infusion product comprising the FREEDOM infusion systems that include the FREEDOM60 syringe driver, the FreedomEdge syringe driver, HIgH-Flo subcutaneous safety needle sets, and precision flow rate tubing. The company also provides education and training materials to clinicians, patients, and patient advocates. It sells its products through direct sales and medical device distributors, as well as online. KORU Medical Systems, Inc. was incorporated in 1980 and is headquartered in Chester, New York.Show more
- Revenue$41M+22.2%
- EBITDA-$2M+61.9%
- Net Income-$3M+56.5%
- EPS (Diluted)-0.06+56.1%
- Gross Margin60.28%-4.9%
- EBITDA Margin-5.26%+68.8%
- Operating Margin-7.23%+62.3%
- Net Margin-6.41%+64.4%
- ROE-15.58%+52.3%
- ROIC-19.47%+50.6%
- Debt/Equity0.21-13.6%
KRMD Key Insights
KORU Medical Systems, Inc. (KRMD) fundamental analysis — strengths, weaknesses & financial health based on data analysis
✓Strengths
- ✓Strong 5Y sales CAGR of 11.2%
- ✓Efficient asset utilization: 1.5x turnover
✗Weaknesses
- ✗Profits declining 16.8% over 5 years
- ✗Negative free cash flow
- ✗Trading more than 30% below 52-week high
- ✗Expensive at 10.9x book value
* These insights are generated automatically based on available financial data. Please conduct your own research before making investment decisions.
KRMD Price & Volume
KORU Medical Systems, Inc. (KRMD) stock price & volume — 10-year historical chart
Loading chart...
KRMD Growth Metrics
KORU Medical Systems, Inc. (KRMD) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years12.88%
5 Years11.21%
3 Years13.81%
TTM23.3%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM56.98%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM56.91%
Return on Capital
10 Years-10.37%
5 Years-25.61%
3 Years-26.24%
Last Year-14.85%
KRMD Recent Earnings
KORU Medical Systems, Inc. (KRMD) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 3/12 qtrs (25%)●Beat Revenue 6/12 qtrs (55%)
Q2 2026Latest
Mar 12, 2026EPS
$0.01
Est $0.02
+50.0%
Revenue
$11M
Est $11M
+0.7%
Q4 2025
Nov 12, 2025EPS
$0.02
Est $0.03
+33.3%
Revenue
$10M
Est $11M
-4.6%
Q3 2025
Aug 6, 2025EPS
$0.01
Est $0.03
+133.3%
Revenue
$10M
Est $10M
+5.5%
Q2 2025
May 7, 2025EPS
$0.03
Est $0.02
-50.0%
Revenue
$10M
Est $9M
+1.9%
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | Mar 12, 2026 | $0.01vs $0.02+50.0% | $11Mvs $11M+0.7% |
| Q4 2025 | Nov 12, 2025 | $0.02vs $0.03+33.3% | $10Mvs $11M-4.6% |
| Q3 2025 | Aug 6, 2025 | $0.01vs $0.03+133.3% | $10Mvs $10M+5.5% |
| Q2 2025 | May 7, 2025 | $0.03vs $0.02-50.0% | $10Mvs $9M+1.9% |
Based on last 12 quarters of dataView full earnings history →
KRMD Peer Comparison
KORU Medical Systems, Inc. (KRMD) competitors in Drug delivery and infusion consumables — business model, growth, and fundamentals comparison
| Company | Market Cap | Stock Price | P/E Ratio (TTM) | Revenue Growth 1Y | Net Margin | Return on Equity (ROE) | FCF Yield | Debt / Equity |
|---|---|---|---|---|---|---|---|---|
 ATRC | 1.42B | 28.01 | -116.71 | 14.88% | -0.83% | -0.95% | 0.18 | |
 INFU | 206.12M | 10.14 | 32.71 | 6.36% | 6.66% | 16.66% | 0.06 | |
 LMAT | 2.51B | 110.22 | 43.74 | 13.53% | 24.35% | 16.19% | 0.47 | |
 BDX | 52.45B | 144.76 | 24.83 | 8.23% | 8.01% | 6.93% | 0.76 | |
 BAX | 8.77B | 16.98 | -9.70 | 5.72% | -9.7% | -16.5% | 1.64 | |
 ICU | 29.11M | 4.87 | -0.73 | -15.51% | -119.2% | |||
 AVNS | 1.15B | 24.72 | -16.93 | 1.95% | -9.69% | -8.91% | 0.17 | |
 MMSI | 3.68B | 61.63 | 28.93 | 11.66% | 9.03% | 8.95% | 0.57 |
Compare KRMD vs Peers
KORU Medical Systems, Inc. (KRMD) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
KRMD Income Statement
KORU Medical Systems, Inc. (KRMD) annual income statement — 10-year revenue, gross profit & net income history
10Y historyFree accessUpdated daily
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales/Revenue | 15.98M | 17.35M | 23.16M | 24.18M | 23.49M | 27.9M | 28.52M | 33.65M | 41.13M | 43.26M |
| Revenue Growth % | 29.96% | 8.62% | 33.47% | 4.38% | -2.84% | 18.76% | 2.23% | 17.98% | 22.23% | 23.3% |
| Cost of Goods Sold | 6.52M | 6.54M | 8.31M | 9.24M | 9.72M | 12.53M | 11.81M | 12.31M | 16.33M | 17.28M |
| COGS % of Revenue | 40.8% | 37.71% | 35.87% | 38.22% | 41.38% | 44.91% | 41.41% | 36.6% | 39.72% | - |
| Gross Profit | 9.46M▲ 0% | 10.81M▲ 14.3% | 14.85M▲ 37.4% | 14.94M▲ 0.6% | 13.77M▼ 7.8% | 15.37M▲ 11.6% | 16.71M▲ 8.7% | 21.33M▲ 27.7% | 24.79M▲ 16.2% | 25.98M▲ 0% |
| Gross Margin % | 59.2% | 62.29% | 64.13% | 61.78% | 58.62% | 55.09% | 58.59% | 63.4% | 60.28% | 60.06% |
| Gross Profit Growth % | 24.95% | 14.3% | 37.4% | 0.55% | -7.81% | 11.62% | 8.71% | 27.67% | 16.23% | - |
| Operating Expenses | 7.97M | 8.75M | 10.85M | 16.19M | 20.8M | 26.15M | 26.98M | 27.78M | 27.77M | 28.8M |
| OpEx % of Revenue | 49.91% | 50.4% | 46.85% | 66.97% | 88.54% | 93.74% | 94.6% | 82.56% | 67.51% | - |
| Selling, General & Admin | 7.91M | 8.2M | 9.77M | 0 | 0 | 0 | 0 | 0 | 23.38M | 18.62M |
| SG&A % of Revenue | 49.53% | 47.23% | 42.19% | - | - | - | - | - | 56.84% | - |
| Research & Development | 60.7K | 241.12K | 740.48K | 1.3M | 2.47M | 4.96M | 5.74M | 5.26M | 4.39M | 4.59M |
| R&D % of Revenue | 0.38% | 1.39% | 3.2% | 5.36% | 10.53% | 17.77% | 20.14% | 15.63% | 10.67% | - |
| Other Operating Expenses | 0 | 0 | 0 | 14.89M | 18.33M | 21.19M | 21.24M | 22.52M | 0 | 1000K |
| Operating Income | 1.48M▲ 0% | 1.16M▼ 21.5% | 585.68K▼ 49.7% | -1.25M▼ 314.2% | -7.03M▼ 460.2% | -10.78M▼ 53.4% | -10.27M▲ 4.7% | -6.45M▲ 37.2% | -2.97M▲ 53.9% | -2.19M▲ 0% |
| Operating Margin % | 9.29% | 6.71% | 2.53% | -5.19% | -29.93% | -38.65% | -36.01% | -19.16% | -7.23% | -5.06% |
| Operating Income Growth % | 301.54% | -21.52% | -49.71% | -314.24% | -460.22% | -53.37% | 4.74% | 37.23% | 53.89% | - |
| EBITDA | 1.79M | 1.47M | 925.91K | -836.19K | -6.57M | -10.19M | -9.4M | -5.67M | -2.16M | -1.4M |
| EBITDA Margin % | 11.22% | 8.49% | 4% | -3.46% | -27.95% | -36.54% | -32.96% | -16.86% | -5.26% | -3.24% |
| EBITDA Growth % | 511.47% | -17.78% | -37.18% | -190.31% | -685.28% | -55.24% | 7.79% | 39.64% | 61.89% | 71.84% |
| D&A (Non-Cash Add-back) | 308.71K | 309.26K | 340.23K | 418.6K | 463.13K | 587.14K | 870.39K | 772.89K | 810.5K | 790.67K |
| EBIT | 1.48M | 2.06M | 4M | 1.19M | -7.03M | -10.78M | -10.27M | -6.45M | -2.97M | -1.64M |
| Net Interest Income | 0 | 28.1K | 80.66K | 42.4K | 13.08K | 145.59K | 561.33K | 444.64K | 293.4K | 220.22K |
| Interest Income | 0 | 28.1K | 80.66K | 42.4K | 13.08K | 145.59K | 561.33K | 444.64K | 293.4K | 220.22K |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Income/Expense | 85.18K | 12.41K | 110.74K | 60.52K | 665.09K | 105.71K | 496.4K | 382.49K | 356.41K | -66.53K |
| Pretax Income | 1.57M▲ 0% | 1.18M▼ 25.0% | 696.42K▼ 40.8% | -1.19M▼ 271.5% | -6.36M▼ 432.9% | -10.68M▼ 67.7% | -9.77M▲ 8.4% | -6.06M▲ 38.0% | -2.62M▲ 56.9% | -2.26M▲ 0% |
| Pretax Margin % | 9.82% | 6.78% | 3.01% | -4.94% | -27.09% | -38.27% | -34.27% | -18.02% | -6.36% | -5.22% |
| Income Tax | 483.07K | 266.38K | 132.07K | 17.8K | -1.8M | -2.01M | 3.97M | 2.89K | 21.89K | 21.89K |
| Effective Tax Rate % | 30.79% | 22.63% | 18.96% | -1.49% | 28.31% | 18.87% | -40.59% | -0.05% | -0.84% | -0.97% |
| Net Income | 1.09M▲ 0% | 910.57K▼ 16.1% | 564.35K▼ 38.0% | -1.21M▼ 314.8% | -4.56M▼ 276.5% | -8.66M▼ 89.8% | -13.74M▼ 58.7% | -6.07M▲ 55.9% | -2.64M▲ 56.5% | -2.28M▲ 0% |
| Net Margin % | 6.8% | 5.25% | 2.44% | -5.01% | -19.42% | -31.05% | -48.18% | -18.03% | -6.41% | -5.27% |
| Net Income Growth % | 302.98% | -16.15% | -38.02% | -314.77% | -276.45% | -89.82% | -58.65% | 55.85% | 56.52% | 56.98% |
| Net Income (Continuing) | 1.09M | 910.57K | 564.35K | -1.21M | -4.56M | -8.66M | -13.74M | -6.07M | -2.64M | -2.28M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | 0.03▲ 0% | 0.02▼ 17.3% | 0.01▼ 38.5% | -0.03▼ 300.7% | -0.10▼ 246.0% | -0.19▼ 90.0% | -0.30▼ 57.9% | -0.13▲ 56.7% | -0.06▲ 56.1% | -0.05▲ 0% |
| EPS Growth % | 300.71% | -17.31% | -38.46% | -300.69% | -246.02% | -90% | -57.89% | 56.67% | 56.08% | 56.91% |
| EPS (Basic) | 0.03 | 0.02 | 0.01 | -0.03 | -0.10 | -0.19 | -0.30 | -0.13 | -0.06 | - |
| Diluted Shares Outstanding | 38.39M | 38.92M | 39.06M | 41.93M | 44.39M | 45M | 45.6M | 45.8M | 46.19M | 46.36M |
| Basic Shares Outstanding | 37.87M | 38.13M | 38.78M | 41.93M | 44.39M | 45M | 45.6M | 45.8M | 46.19M | 46.36M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - | - |
KRMD Balance Sheet
KORU Medical Systems, Inc. (KRMD) balance sheet — assets, liabilities & shareholders' equity
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Current Assets | 7.93M | 9.03M | 11.88M | 37.53M | 37.32M | 29.8M | 20.26M | 19.13M | 19.99M | 20.59M |
| Cash & Short-Term Investments | 4.24M | 3.74M | 5.87M | 27.32M | 25.33M | 17.41M | 11.48M | 9.58M | 8.87M | 8.77M |
| Cash Only | 3.97M | 3.74M | 5.87M | 27.32M | 25.33M | 17.41M | 11.48M | 9.58M | 8.87M | 8.77M |
| Short-Term Investments | 263.27K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.86M | 1.43M | 3.23M | 2.57M | 3.59M | 3.56M | 4.05M | 6M | 6.53M | 6.32M |
| Days Sales Outstanding | 42.54 | 29.99 | 50.97 | 38.84 | 55.83 | 46.57 | 51.77 | 65.07 | 57.95 | 49.47 |
| Inventory | 1.66M | 2.1M | 2.39M | 6.83M | 6.11M | 6.4M | 3.48M | 2.8M | 3.68M | 4.48M |
| Days Inventory Outstanding | 92.87 | 117.36 | 104.92 | 269.78 | 229.29 | 186.62 | 107.6 | 83.1 | 82.19 | 87.21 |
| Other Current Assets | 0 | 1.52M | 0 | 0 | 718.22K | 972.4K | 28.89K | 749.85K | 908.54K | 1.03M |
| Total Non-Current Assets | 1.35M | 1.51M | 2M | 2.39M | 3.97M | 12.53M | 8.21M | 8.09M | 8.21M | 8M |
| Property, Plant & Equipment | 836.28K | 858.78K | 985.58K | 1.4M | 1.2M | 7.67M | 7.35M | 7.26M | 7.43M | 7.19M |
| Fixed Asset Turnover | 19.10x | 20.21x | 23.50x | 17.21x | 19.54x | 3.64x | 3.88x | 4.64x | 5.54x | 6.04x |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 483.82K | 632.16K | 807.13K | 843.59K | 808.81K | 787.18K | 754.36K | 730.28K | 684.84K | 711.21K |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 31.58K | 19.58K | 19.58K | 145.09K | 1.96M | 4.07M | 98.97K | 98.97K | 98.97K | 395.88K |
| Total Assets | 9.28M▲ 0% | 10.55M▲ 13.6% | 13.88M▲ 31.6% | 39.92M▲ 187.6% | 41.29M▲ 3.4% | 42.33M▲ 2.5% | 28.46M▼ 32.8% | 27.22M▼ 4.4% | 28.2M▲ 3.6% | 28.59M▲ 0% |
| Asset Turnover | 1.72x | 1.65x | 1.67x | 0.61x | 0.57x | 0.66x | 1.00x | 1.24x | 1.46x | 1.58x |
| Asset Growth % | 13.59% | 13.62% | 31.64% | 187.56% | 3.44% | 2.52% | -32.77% | -4.37% | 3.61% | 1.07% |
| Total Current Liabilities | 1.59M | 1.58M | 2.41M | 3.67M | 4.79M | 6.96M | 4.45M | 7.2M | 8.19M | 8.85M |
| Accounts Payable | 454.4K | 453.5K | 572.66K | 624.92K | 1.23M | 2.39M | 975.19K | 1.65M | 2.27M | 2.64M |
| Days Payables Outstanding | 25.44 | 25.3 | 25.16 | 24.68 | 46.09 | 69.69 | 30.14 | 48.9 | 50.67 | 41.56 |
| Short-Term Debt | 0 | 0 | 142.18K | 0 | 508.58K | 433.3K | 314.34K | 271.15K | 538.36K | 548.05K |
| Deferred Revenue (Current) | 0 | 3.76K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 796.39K | 688.65K | 1.36M | 0 | 90K | 257.34K | 512.52K | 29.27K | 5.39M | 8.3M |
| Current Ratio | 5.00x | 5.70x | 4.94x | 10.24x | 7.79x | 4.28x | 4.55x | 2.66x | 2.44x | 2.44x |
| Quick Ratio | 3.95x | 4.37x | 3.95x | 8.37x | 6.51x | 3.36x | 3.77x | 2.27x | 1.99x | 1.99x |
| Cash Conversion Cycle | 109.97 | 122.05 | 130.74 | 283.94 | 239.02 | 163.49 | 129.23 | 99.26 | 89.48 | 95.13 |
| Total Non-Current Liabilities | 25.44K | 0 | 239.49K | 95.55K | 0 | 4.05M | 3.65M | 3.2M | 2.96M | 2.82M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.96M | 2.82M |
| Capital Lease Obligations | 0 | 0 | 239.49K | 95.55K | 0 | 4.05M | 3.65M | 3.2M | 0 | 8.7M |
| Deferred Tax Liabilities | 21.68K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 3.76K | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Total Liabilities | 1.61M | 1.58M | 2.65M | 3.76M | 4.79M | 11.01M | 8.11M | 10.4M | 11.15M | 11.67M |
| Total Debt | 0 | 0 | 381.68K | 239.49K | 604.14K | 4.93M | 4.45M | 3.99M | 3.5M | 3.37M |
| Net Debt | -3.97M | -3.74M | -5.49M | -27.08M | -24.73M | -12.48M | -7.04M | -5.59M | -5.38M | -5.4M |
| Debt / Equity | - | - | 0.03x | 0.01x | 0.02x | 0.16x | 0.22x | 0.24x | 0.21x | 0.21x |
| Debt / EBITDA | - | - | 0.41x | - | - | - | - | - | - | -2.40x |
| Net Debt / EBITDA | -2.22x | -2.54x | -5.93x | - | - | - | - | - | - | 3.86x |
| Interest Coverage | - | - | - | - | - | - | - | - | - | - |
| Total Equity | 7.67M▲ 0% | 8.96M▲ 16.8% | 11.24M▲ 25.4% | 36.16M▲ 221.8% | 36.5M▲ 1.0% | 31.33M▼ 14.2% | 20.35M▼ 35.0% | 16.81M▼ 17.4% | 17.05M▲ 1.4% | 16.92M▲ 0% |
| Equity Growth % | 14.88% | 16.83% | 25.39% | 221.79% | 0.95% | -14.18% | -35.03% | -17.39% | 1.39% | -13.87% |
| Book Value per Share | 0.20 | 0.23 | 0.29 | 0.86 | 0.82 | 0.70 | 0.45 | 0.37 | 0.37 | 0.36 |
| Total Shareholders' Equity | 7.67M | 8.96M | 11.24M | 36.16M | 36.5M | 31.33M | 20.35M | 16.81M | 17.05M | 16.92M |
| Common Stock | 407.31K | 409.33K | 422.4K | 466.8K | 480.44K | 488.62K | 490.9K | 493.78K | 497.91K | 499.33K |
| Retained Earnings | 3.39M | 4.3M | 4.86M | 3.65M | -910.07K | -9.57M | -23.31M | -29.38M | -32.02M | -32.82M |
| Treasury Stock | -344.2K | -344.2K | -344.2K | -3.84M | -3.84M | -3.84M | -3.84M | 0 | 0 | 0 |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
KRMD Cash Flow Statement
KORU Medical Systems, Inc. (KRMD) cash flow — operating, investing & free cash flow history
| Line item | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | Dec'25 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations | 899.91K | 1.48M | 320.62K | -743.32K | -4.32M | -5.4M | -4.89M | -319.72K | 462.4K | 462.4K |
| Operating CF Margin % | 5.63% | 8.53% | 1.38% | -3.07% | -18.39% | -19.37% | -17.16% | -0.95% | 1.12% | - |
| Operating CF Growth % | 371.37% | 64.42% | -78.33% | -331.84% | -481.11% | -25.12% | 9.47% | 93.47% | 244.63% | -3931.46% |
| Net Income | 1.09M | 910.57K | 564.35K | -1.21M | -4.56M | -8.66M | -13.74M | -6.07M | -2.64M | -2.28M |
| Depreciation & Amortization | 308.71K | 309.26K | 340.23K | 418.6K | 463.13K | 587.14K | 870.39K | 888.47K | 810.5K | 790.67K |
| Stock-Based Compensation | 129.7K | 366.08K | 1.2M | 1.62M | 2.71M | 3.08M | 2.77M | 2.62M | 2.71M | 1.98M |
| Deferred Taxes | -60.75K | -23.14K | -186.78K | 62.97K | -1.82M | -2.03M | 3.97M | 0 | 0 | 0 |
| Other Non-Cash Items | 1.58M | -66.98K | -56.45K | 1.3M | -1.01K | 212.55K | 37.82K | 934.33K | -104.54K | -367.64K |
| Working Capital Changes | -349.85K | -16.13K | -1.55M | -2.93M | -1.11M | 1.4M | 1.2M | 1.3M | -319.17K | 586.05K |
| Change in Receivables | -418.86K | 475.66K | -1.8M | 669.74K | -1.74M | -220.17K | 457.18K | -1.68M | -489.2K | -33.12K |
| Change in Inventory | -304.98K | -445.2K | -284.6K | -4.44M | 723.43K | -298.53K | 2.92M | 677.63K | -874.46K | -1.2M |
| Change in Payables | -318.03K | -900 | 119.16K | 52.26K | 602.61K | 1.16M | -1.42M | 0 | 617.5K | 1.54M |
| Cash from Investing | -219.28K | -1.73M | 1.31M | -1.04M | -366.17K | -2.8M | -814.6K | -1.33M | -949.79K | -592.84K |
| Capital Expenditures | -218.33K | -481.17K | -425.54K | -920.6K | -346.18K | -2.76M | -782.95K | -1.3M | -932.52K | -535.24K |
| CapEx % of Revenue | 1.37% | 2.77% | 1.84% | 3.81% | 1.47% | 9.9% | 2.75% | 3.86% | 2.27% | - |
| Acquisitions | 0 | 481.17K | 217.82K | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - |
| Other Investing | -955 | -475.17K | -6.54K | -115.55K | -19.99K | -40.51K | -31.65K | -35.62K | -17.27K | -57.59K |
| Cash from Financing | -19.36K | 14.43K | 501.3K | 23.22M | 2.71M | 279.49K | -218.87K | -248.53K | -221.35K | -89.76K |
| Debt Issued (Net) | 0 | 0 | -4.78K | -5.3K | 505.94K | -127.14K | -218.87K | -107.96K | -379.98K | -81.99K |
| Equity Issued (Net) | -19.36K | 51.25K | 506.08K | 23.23M | 2.2M | 406.62K | 0 | -97.38K | 186.16K | 158.63K |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | -19.36K | -36.82K | -2.82K | -3.5M | 0 | 0 | 0 | -97.38K | 0 | -27.54K |
| Other Financing | 0 | -36.82K | 0 | 0 | 0 | 0 | 0 | -43.19K | -27.54K | -166.4K |
| Net Change in Cash | -227.41K▲ 0% | -235.73K▼ 3.7% | 2.13M▲ 1004.5% | 21.44M▲ 905.8% | -1.98M▼ 109.2% | -7.93M▼ 300.3% | -5.93M▲ 25.2% | -1.9M▲ 67.9% | -708.74K▲ 62.7% | 31.94K▲ 0% |
| Free Cash Flow | 681.59K▲ 0% | 998.5K▲ 46.5% | -104.92K▼ 110.5% | -1.8M▼ 1619.9% | -4.69M▼ 160.2% | -8.21M▼ 74.8% | -5.71M▲ 30.5% | -1.62M▲ 71.7% | -470.11K▲ 70.9% | 179.29K▲ 0% |
| FCF Margin % | 4.27% | 5.75% | -0.45% | -7.46% | -19.99% | -29.42% | -20.01% | -4.81% | -1.14% | 0.41% |
| FCF Growth % | 191.27% | 46.5% | -110.51% | -1619.87% | -160.17% | -74.79% | 30.45% | 71.66% | 70.93% | 109.86% |
| FCF per Share | 0.02 | 0.03 | -0.00 | -0.04 | -0.11 | -0.18 | -0.13 | -0.04 | -0.01 | -0.01 |
| FCF Conversion (FCF/Net Income) | 0.83x | 1.62x | 0.57x | 0.61x | 0.95x | 0.62x | 0.36x | 0.05x | -0.18x | -0.08x |
| Interest Paid | 0 | 0 | 342 | 27.74K | 13.24K | 28.49K | 50.83K | 71.93K | 0 | 2.18K |
| Taxes Paid | 0 | 378K | 130.88K | 321.98K | 1.9K | 0 | 3.16K | 0 | 0 | 0 |
KRMD Key Ratios
KORU Medical Systems, Inc. (KRMD) financial ratios — P/E, ROE, debt and 30+ core market and balance-sheet ratios
| Metric | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | 15.14% | 10.95% | 5.59% | -5.11% | -12.56% | -25.54% | -53.18% | -32.64% | -15.58% | -13.61% |
| Return on Invested Capital (ROIC) | 31.54% | 19.59% | 8.01% | -12.69% | -50.57% | -52.83% | -47.9% | -39.4% | -19.47% | -19.47% |
| Gross Margin | 59.2% | 62.29% | 64.13% | 61.78% | 58.62% | 55.09% | 58.59% | 63.4% | 60.28% | 60.06% |
| Net Margin | 6.8% | 5.25% | 2.44% | -5.01% | -19.42% | -31.05% | -48.18% | -18.03% | -6.41% | -5.27% |
| Debt / Equity | - | - | 0.03x | 0.01x | 0.02x | 0.16x | 0.22x | 0.24x | 0.21x | 0.21x |
| FCF Conversion | 0.83x | 1.62x | 0.57x | 0.61x | 0.95x | 0.62x | 0.36x | 0.05x | -0.18x | -0.08x |
| Revenue Growth | 29.96% | 8.62% | 33.47% | 4.38% | -2.84% | 18.76% | 2.23% | 17.98% | 22.23% | 23.3% |
KRMD SEC Filings & Documents
KORU Medical Systems, Inc. (KRMD) SEC filings — annual & quarterly reports (10-K, 10-Q)
KRMD Frequently Asked Questions
KORU Medical Systems, Inc. (KRMD) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
KORU Medical Systems, Inc. (KRMD) reported $43.3M in revenue for fiscal year 2025. This represents a 1994% increase from $2.1M in 1999.
KORU Medical Systems, Inc. (KRMD) grew revenue by 22.2% over the past year. This is strong growth.
KORU Medical Systems, Inc. (KRMD) reported a net loss of $2.3M for fiscal year 2025.
Dividend & Returns
KORU Medical Systems, Inc. (KRMD) has a return on equity (ROE) of -15.6%. Negative ROE indicates the company is unprofitable.
KORU Medical Systems, Inc. (KRMD) generated $0.2M in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
Explore More KRMD
KORU Medical Systems, Inc. (KRMD) financial analysis — history, returns, DCA and operating performance tools
Total Return Calculator
Historical returns with dividends reinvested
DCA Calculator
Dollar cost averaging vs lump sum
Dividend History
Yield, growth, payout safety & DRIP
Earnings History
EPS trends, net income & profitability
Price History
Long-term charts & historical price data
Revenue History
Sales growth patterns & revenue breakdown
Financial Ratios
30 years of market, efficiency and balance-sheet ratios
Valuation
DCF intrinsic value, peer multiples & estimates